top of page

Peer-reviewed Publications

  • Hepatitis A vaccination coverage in adults with chronic liver disease in primary care in England. Meza-Torres B, Jamie G, et al. Pericleous M. Lancet Public Health. 2025.

  • Hepatocellular Carcinoma (HCC): An update on risk factors, surveillance, diagnosis and treatment strategies. Mathew S, Pericleous M, et al. World J Gastroenterol. 2024.

  • Regional variation in characteristics of patients with decompensated cirrhosis admitted to hospitals in the UK. Trainee Collaborative for Research and Audit in Hepatology UK. Lancet Gastroenterol Hepatol. 2023.

  • Characteristics and outcomes of NAFLD patients admitted with decompensated cirrhosis. Trainee Collaborative for Research and Audit in Hepatology UK. J Hepatol. 2023.

  • Diagnostic modalities of NAFLD: from biomarkers to multi-omics approaches. Martinou E, Pericleous M, et al. Diagnostics (Basel). 2022.

  • Defining and characterising a toolkit for the development of a successful European registry for rare liver diseases: a model for building a rare disease registry. Pericleous M, Kelly C, Ala A, de Lusignan S, et al. Orphanet J Rare Dis. 2022.

image 3_edited_edited.jpg

  • Improving uptake of hepatitis B and hepatitis C testing in South Asian migrants in community and faith settings using educational interventions: A prospective descriptive study. Kelly C, Pericleous M, et al.

  • Clinical Ontologies Improve Case Finding of Primary Biliary Cholangitis in UK Primary and Secondary Care. Pericleous M, Kelly C, McGee C, Sherlock J, Yonova I, Byford R, Ferreira F, de Lusignan S, Ala A.

  • The role of the chronic care model in promoting the management of the patient with rare liver disease. Pericleous M, Kelly C, Ala A, de Lusignan S.

  • Pregnancy-associated liver disease: a curriculum-based review. Pericleous M, et al.

  • Interventions to improve the uptake of screening across a range of conditions in Ethnic Minority Groups: a systematic review. Kelly C, Pericleous M, et al.

  • Wilson disease: more than meets the eye. Pericleous M, et al.

  • The clinical management of hereditary haemochromatosis. Pericleous M, et al.

  • Well-differentiated bronchial neuroendocrine tumors: Clinical management and outcomes in 105 patients. Pericleous M, Toumpanakis C, Meyer T, Caplin ME, et al.

  • Wolman's disease and cholesteryl ester storage disorder: the phenotypic spectrum of lysosomal acid lipase deficiency. Pericleous M, et al.

  • Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Pericleous M, et al.

  • The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: a review of current guidelines and recommendations. Pericleous M, et al.

  • Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes. Pericleous M, Caplin ME, Yu D, Morgan-Rowe L, Tsochatzis E, Toumpanakis C.

  • Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. Pericleous M, et al.

  • The role of dietary factors in prevention and progression of breast cancer. Pericleous M, et al.

  • Prostate cancer and the influence of dietary factors and supplements: a systematic review. Pericleous M, et al.

  • The impact of diet and nutrition in the prevention and progression of hepatocellular carcinoma. Pericleous M, et al.

  • Nutrition and pancreatic cancer. Pericleous M, et al.

  • Diet and supplements and their impact on colorectal cancer. Pericleous M, et al.

  • Using an 'action set' for the management of acute upper gastrointestinal bleeding. Pericleous M, Murray C, Kaul A, et al.

  • Pancreatic adenocarcinoma in a patient with multiple endocrine neoplasia 1 syndrome. Pericleous M, et al.

  • Appendiceal goblet cell carcinoid tumour: a case of unexpected lung metastasis. Baneke A, Toumpanakis C, Pericleous M, et al.

  • Gastric mixed adenoneuroendocrine carcinoma with a trilineage cell differentiation: case report and review of the literature. Pericleous M, Caplin ME, Luong TV, et al.

  • Hepatobiliary disease associated with hypereosinophilia: a report of two patients and a review of the literature. Pericleous M, Mathew S, Lloyd M, Berry P, Lewis H, Cheent K, Ramu A, Kousparos G, Yousuf K, Ala A.

  • Bronchial neuroendocrine tumours: A retrospective review of management and outcomes in 116 patients. Pericleous M, Lumgair H, Reiner J, Marelli L, Caplin ME, Meyer T, Toumpanakis C.

  • Diagnostic features and management outcomes in bronchopulmonary neuroendocrine tumours: A clinical study of 116 patients. Pericleous M, Toumpanakis C, Lumgair H, et al. ENETS Conference. 2012.

Abstract presentations at national and international meetings

  • Real-World Effectiveness of UDCA-Elafibranor Combination versus Obeticholic Acid and Bezafibrate Switch Protocols: A Comparative Analysis – European Association for the Study of the Liver (EASL) Congress, Barcelona, 2026.

  • Audit of transarterial chemoembolisation (TACE) and embolisation (TAE) for HCC – BASL, Belfast, 2025.

  • Early real-world evaluation of Elafibranor in primary biliary cholangitis – BASL, Belfast, 2025.

  • Evaluation of regional hepatocellular carcinoma surveillance practice in an MDT setting – BASL, Belfast, 2025.

  • HCC management in a tertiary HPB centre: lessons from South East England – EASL Liver Cancer Summit, 2023.

  • Ontology-based case finding of primary biliary cholangitis in UK primary care databases – AASLD, San Francisco, 2018.

  • Patient registries for orphan liver diseases: translating policy into practice in the EU – AASLD, 2018.​

  • Development of a real-world regional PBC registry linking primary and secondary care – AASLD, 2018.

​​​​

  • Educational interventions to improve viral hepatitis testing in UK South Asian populations – AASLD, 2018.

  • Lysosomal acid lipase activity in NAFLD patients in a regional hepatology cohort – BASL, York, 2018.

  • Rare liver disease registries: translating policy into clinical practice – BASL, York, 2018.

  • Blueprint for development of rare liver disease registries – BASL, York, 2018.

  • Development of a UK regional PBC registry with primary–secondary care linkage – BASL, York, 2018.

  • Ontology approaches for improved PBC case finding – BASL, York, 2018.

  • Educational intervention for viral hepatitis case-finding in South Asian communities – BASL, York, 2018.

  • Impact of NHS England commissioning of DAAs for hepatitis C – BASL, York, 2018.

  • Real-world adverse events with direct-acting antivirals for hepatitis C – BASL, York, 2018.

  • Development of a rare liver disease registry blueprint – UEG Week, Vienna, 2018.

  • Regional PBC registry linking primary and secondary care – UEG Week, Vienna, 2018.

  • Translating policy to practice in rare liver disease registries – UEG Week, Vienna, 2018.

  • Development of an alcohol liaison service: clinical outcomes – AASLD, Washington, 2017.

  • Antenatal clinic as a screening platform for alcohol-related harm – AASLD, 2017.

  • Barriers to testing for chronic viral hepatitis in UK South Asian populations – AASLD, 2017.

  • Chronic care model in primary biliary cholangitis – BASL, Coventry, 2017.

  • Is PBC under-recognised in primary care? – BASL, Coventry, 2017.

  • Antenatal screening for alcohol-related harm – BASL, Coventry, 2017.

  • Interpretation of low lysosomal acid lipase levels in hepatology practice – BASL, Coventry, 2017.

  • Integrated care models for orphan liver diseases – BASL, Coventry, 2017.

  • Barriers to viral hepatitis testing in UK South Asians – national NIHR study.

  • Alcohol liaison service outcomes – BSG, Manchester, 2017.

  • Clinical significance of low lysosomal acid lipase levels – BSG, Manchester, 2017.

  • National patterns of IgG4-related disease testing in the UK – AASLD, Boston, 2016.

  • Role of repeat liver biopsy in autoimmune hepatitis – AASLD, Boston, 2016.

  • IgG4-related disease: testing patterns and case-finding – BASL, Manchester, 2016.

  • Repeat liver biopsy in autoimmune hepatitis: clinical experience – BASL, Manchester, 2016.

  • HCC management outcomes in a tertiary HPB centre – BASL, Manchester, 2016.

  • Trends in serum IgG4 testing in hepatology practice – Falk Symposium, Lucerne, 2016.

  • National survey of IgG4-related disease experience in the UK – Falk Symposium, 2016.

  • Lessons from HCC management in South East England – Falk Symposium, 2016.

  • Management of hepatocellular carcinoma in a tertiary HPB centre – BSG, Liverpool, 2016.

  • Electrolyte replacement practices in hospitalised patients – Buckinghamshire Foundation Forum.

  • Hepatitis B household contact testing practices.

  • Role of repeat liver biopsy in autoimmune hepatitis outcomes.

  • Hypereosinophilic autoimmune liver disease: case series.

  • Allopurinol dose escalation in IBD patients with azathioprine hepatotoxicity – BSG, Manchester, 2014.

  • Hepatic artery embolisation outcomes in neuroendocrine tumours – BSG, Glasgow, 2013.

  • Diagnostic outcomes in goblet cell appendiceal NETs – BSG, Liverpool, 2012.

  • Bronchial neuroendocrine tumours: management and outcomes in 116 patients – ASCO, 2012.

  • Bronchopulmonary NETs: diagnostic and management outcomes – ENETS, Copenhagen, 2012.

  • Goblet cell appendiceal NETs: recurrence and survival outcomes – ENETS, Copenhagen, 2012.

  • Mixed adenoneuroendocrine carcinoma: histology and nuclear imaging – UKINETS, London, 2011.

  • Improving management of upper gastrointestinal bleeding – SAM International Conference, Edinburgh, 2010.

  • Upper GI bleeding audit cycle – BSG, Birmingham, 2011.

  • Improving upper GI bleeding management pathways – SAM Meeting, Edinburgh.

  • Breast cancer incidence in UK Asian women compared with Caucasian populations – San Antonio Breast Cancer Symposium, Texas, 2008.

bottom of page